RNS Number:0985N
Chiron Corporation
03 July 2003

Embargoed until 7.00 a.m. on 3 July 2003


Not for release, publication or distribution in or into Canada, Australia or
Japan



                                                                     3 July 2003



                             Recommended Cash Offer
                                       by
                              UBS Investment Bank*
                                  on behalf of
                              Chiron UK-1 Limited
                a wholly-owned subsidiary of Chiron Corporation
                         and (in the United States) by
                              Chiron UK-1 Limited
                                      for
                         PowderJect Pharmaceuticals plc





UK ANTI-TRUST CLEARANCE OBTAINED


Chiron Corporation ("Chiron") announces that in connection with the recommended
cash offer (the "Offer") being made by UBS Investment Bank on behalf of Chiron
UK-1 Limited ("Chiron UK"), a wholly-owned subsidiary of Chiron, and in the
United States by Chiron UK, for the entire issued and to be issued share capital
of PowderJect Pharmaceuticals plc ("PowderJect"), approval of the proposed
acquisition was obtained from the Secretary of State for Trade and Industry on 2
July 2003.  Accordingly, the UK anti-trust condition of the Offer has been
satisfied.


Forms of Acceptance not yet returned should be completed and returned in
accordance with the instructions set out in the offer document dated 19 May 2003
(the "Offer Document") and in the Form of Acceptance so as to be received as
soon as possible and, in any event, by not later than 3.00 p.m. (London time) or
10.00 a.m. (New York City time) on 7 July 2003.


Unless the context otherwise requires, defined terms used in this announcement
shall have the meanings given to them in the Offer Document.


Enquiries:


UBS Investment Bank (financial      Liam Beere             Tel: +44 20 7568 2286
adviser to Chiron UK and Chiron)
                                    Harrison Wehner        Tel: +44 20 7567 6612

Lloyds TSB Registrars (receiving                              Tel: 0870 600 0673
agent)
                                                (or  +44 1903 702767, if outside
                                                              the UK)



The availability of the Offer to PowderJect Shareholders who are not resident in
the United Kingdom may be affected by the laws of their relevant jurisdiction.
Such persons should inform themselves of, and observe, any applicable legal or
regulatory requirements of their jurisdiction.


The Offer is not being made, directly or indirectly, in or into Canada,
Australia or Japan and the Offer is not capable of acceptance from or within
Canada, Australia or Japan. Accordingly, copies of this announcement and any
related documents are not being, and must not be, directly or indirectly, mailed
or otherwise forwarded, distributed or sent in, into or from Canada, Australia
or Japan and persons receiving this announcement (including custodians, nominees
and trustees) must not mail or otherwise distribute or send it in, into or from
such jurisdictions as doing so may render invalid any purported acceptance of
the Offer.


UBS Limited, which is regulated by the Financial Services Authority in the
United Kingdom, is acting as financial adviser to Chiron and Chiron UK and no
one else in connection with the Offer and will not be responsible to anyone
other than Chiron or Chiron UK for providing the protections afforded to clients
of UBS Limited, nor for providing advice in relation to the Offer.



* UBS Investment Bank (formerly known as UBS Warburg) is the advertising name
for UBS Limited.




                      This information is provided by RNS
            The company news service from the London Stock Exchange
END

OUPRTMRTMMTMBMJ